Previsioni

Il prezzo obiettivo medio degli analisti è +18,03€ (+22,99%). La mediana è +18,03€ (+22,99%).

Acquista	4
Mantieni	8
Vendi	1

Notizie Vai al feed delle notizie

Viatris beats Q2 expectations and raises full-year outlook

Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » Altro su de.investing.com
Viatris receives FDA approval for once-weekly contraceptive patch Gwyn Lo

The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » Altro su de.investing.com
Viatris hits 52‑week high of $17.68 after strong quarterly results and Phase‑3 success

Viatris shares rose to a 52‑week high of $17.68, driven by strong price performance (+90.82% year‑to‑date) and a market capitalization of $20.6 billion. The company beat Q1‑2026 expectations with adjusted EPS of $0.59 (consensus $0.51) and revenue of $3.52 billion. Viatris also reported positive Phase‑3 results for the IgAN drug VR‑205 in Japan, and the FDA has accepted the approval filing for a rapid‑acting meloxicam formulation (PDUFA date 27.12.2026). InvestingPro rates the stock as undervalued; management has executed aggressive buybacks and expects to be profitable this year. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, VIATRIS INC. O.N. ha già distribuito 0,20€ di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, VIATRIS INC. O.N. ha registrato ricavi pari a 3,29Mld€ e un utile netto di −104,09M€

(EUR)	giu 2026	YoY
Ricavi	+3,29Mld	8,31%
Utile lordo	+1,28Mld	12,85%
Utile netto	−104,09M	2.567,20%
EBITDA	+572,43M	16,77%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+16,85Mld€
Numero di azioni	1,16Mld
Massimo/minimo a 52 settimane	+15,79€ - +8,10€
Rendimento da dividendo	+2,85%
Dividendi TTM	+0,41€
Prossimo dividendo	+0,10€
Beta	0,89
Rapporto P/E	−46,81
Rapporto PEG	−3,21
Rapporto P/B	+1,37
Rapporto P/S	+1,33

Profilo aziendale

Viatris Inc. ist ein weltweit tätiges Gesundheitsunternehmen. Das Unternehmen ist in vier Segmenten tätig: Developed Markets, Greater China, JANZ und Emerging Markets. Es bietet verschreibungspflichtige Markenmedikamente, Generika, komplexe Generika, Biosimilars und aktive pharmazeutische Inhaltsstoffe (APIs). Das Unternehmen bietet Medikamente in verschiedenen therapeutischen Bereichen an, darunter nichtübertragbare und Infektionskrankheiten, Biosimilars in den Bereichen Onkologie, Immunologie, Endokrinologie, Augenheilkunde und Dermatologie sowie APIs für die Bereiche Antibiotika, Mittel für das zentrale Nervensystem, Antihistaminika/Antiasthmatika, Herz-Kreislauf-Medikamente, Virostatika, Antidiabetika, Antimykotika und Protonenpumpenhemmer sowie unterstützende Dienstleistungen wie Diagnosekliniken, Aufklärungsseminare und digitale Hilfsmittel, die Patienten helfen, ihre Gesundheit besser zu verwalten. Das Unternehmen bietet seine Arzneimittel in Form von festen oralen Dosen, injizierbaren Arzneimitteln, komplexen Darreichungsformen und Wirkstoffen dem Einzelhandel und Apotheken, Großhändlern und Distributoren, Kostenträgern, Versicherern und Regierungen sowie Institutionen an. Das Unternehmen vertreibt seine Produkte über pharmazeutische Großhändler/Vertriebsunternehmen, pharmazeutische Einzelhändler, institutionelle Apotheken, Versand- und E-Commerce-Apotheken sowie Spezialapotheken. Es vertreibt seine Produkte unter den Namen Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine und Yupelri; Norvasc und Viagra; AMITIZA, Lipacreon und Effexor; und Celebrex und ARV, sowie bietet Biosimilars Franchises, einschließlich Fulphila, Ogivri, Hulio und SEMGLEE. Das Unternehmen hat Kooperations- und Lizenzvereinbarungen mit Revance Therapeutics, Inc, Momenta Pharmaceuticals, Inc, Theravance Biopharma, Inc, Biocon Ltd. und Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. wurde 1961 gegründet und hat seinen Hauptsitz in Canonsburg, Pennsylvania.

Nome	VIATRIS INC. O.N.
CEO	Scott Andrew Smith
Sede centrale	Canonsburg, pa Stati Uniti
Sito web	viatris.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	17/03/1980
Dipendenti	30.000